ストックスクリーナーアプリを入手
17.10
3.28%
-0.58
プレマーケット:
20.50
3.40
+19.88%
前日終値:
$17.68
開ける：
$17.92
24時間の取引高:
791.39K
Relative Volume:
0.79
時価総額：
$1.05B
収益：
$13.73M
当期純損益:
$-114.48M
株価収益率:
-9.2844
EPS:
-1.8418
ネットキャッシュフロー:
$-78.49M
1週間 パフォーマンス:
-15.51%
1か月 パフォーマンス:
+3.51%
6か月 パフォーマンス:
+21.45%
1年 パフォーマンス:
-31.93%
1日の値動き範囲:
$17.05
$17.94
1週間の範囲:
$17.05
$20.25
52週間の値動き範囲:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
名前
Janux Therapeutics Inc
セクター
電話
(858) 751-4493
住所
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
17.10 | 1.05B | 13.73M | -114.48M | -78.49M | -1.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-08-24 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2026-04-20 | ダウングレード | Barclays | Overweight → Underweight |
| 2026-04-15 | ダウングレード | UBS | Buy → Neutral |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-10 | 開始されました | Stifel | Buy |
| 2025-09-10 | 開始されました | Truist | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-07-11 | 開始されました | Raymond James | Outperform |
| 2024-12-03 | 繰り返されました | BTIG Research | Buy |
| 2024-12-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-11-22 | 開始されました | Leerink Partners | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-05-30 | 開始されました | Scotiabank | Sector Perform |
| 2024-03-21 | 開始されました | BTIG Research | Buy |
| 2024-03-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 開始されました | Wedbush | Outperform |
| 2022-11-14 | 開始されました | William Blair | Outperform |
すべてを表示
Janux Therapeutics Inc (JANX) 最新ニュース
Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily
Janux’s JANX014 Prostate Cancer Trial Advances, Keeping Early-Stage Upside in Play - TipRanks
Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44% - qz.com
Wolfe Research Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23 - Moomoo
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com Canada
Wolfe Research upgrades Janux stock rating on autoimmune data - investing.com
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know - TradingView
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - Sahm
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo
Janux (JANX) Latest Quarter: EPS Lands Above Forecast; Market Reaction: Shares Finish 3.30% Higher on the DayEstimate Revision Count - vinanet.vn
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA) - The Globe and Mail
Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund - Stock Titan
Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management - Stock Titan
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
William Blair Maintains Janux Therapeutics(JANX.US) With Buy Rating - moomoo.com
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Janux Therapeutics (JANX) Gains 0.91% as Shares Firmly Hold Above $15.84 SupportHigh Conviction Picks - Vinanet
Equities Analysts Set Expectations for JANX Q3 Earnings - MarketBeat
HC Wainwright Has Negative Outlook of JANX FY2030 Earnings - MarketBeat
Why (JANX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile - Yahoo Finance
Janus Living Prices Share Offering - marketscreener.com
Janux Therapeutics Inc (JANX) Stock News Today - TradingKey
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating - Moomoo
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results - simplywall.st
Janux Therapeutics (NASDAQ:JANX) Announces Earnings Results - MarketBeat
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside - TradingView
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - BioSpace
JANX Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusRevenue Guidance Update - vinanet.vn
Janux Therapeutics earnings missed by $0.08, revenue fell short of estimates - Investing.com Canada
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Janux Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Janux Therapeutics 2Q 2026: Revenue $10.3M, EPS $(0.35) — 10-Q Summary - TradingView
JANX: Clinical pipeline advanced and net loss narrowed, supported by nearly $1B in liquidity - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q2 Revenue $10.3M, vs. FactSet Est of $19.1M - marketscreener.com
JANX: Revenue from BMS collaboration boosted H1 2026 results; net loss narrowed, cash remains strong - TradingView
Janux Therapeutics (NASDAQ: JANX) posts Q2 loss on collaboration revenue - Stock Titan
Janux Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Janux Therapeutics posts $970.9M cash; Q2 net loss $22.0M and revenue $10.3M - TradingView
BRIEF-Janux Therapeutics Q2 Basic EPS USD -0.35 - TradingView
8-K: Janux Therapeutics | 8-K: Current report - moomoo.com
JANX Q2'26 Earnings: revenue estimate is 19.07M USD - TradingView
Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech Gamble with 142% Potential Upside - DirectorsTalk Interviews
Janux Therapeutics (JANX) Holds at $15.32 as Biotech Names Find FootingKAMA Signal - vinanet.vn
Janux Therapeutics (JANX) Pulls Back to $15.17 as Biotech Volatility PersistsLast Point Resistance - vinanet.vn
Form 4 Janux Therapeutics Inc For: 31 July By Investing.com - Investing.com Canada
Janux Therapeutics Inc (JANX) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
1.67%
大文字化:
|
ボリューム (24 時間):